Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
78.60 ^USD	-9.83%		-16.23%	-23.05%

Mar. 30	Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan	RE
Mar. 30	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI

Transcript : Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01

Published on 03/11/2026 at 02:20 pm EDT - Modified on 03/11/2026 at 03:21 pm EDT

S&P Capital IQ

Presenter Speech
Luke Sergott (Analysts)

Good afternoon, everybody. I'm Luke Sergott, I cover life science tools and diagnostics here at Barclays. With me, I have AmirAli Talasaz, co-CEO; and Mike

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Guardant Health, Inc.

Mar. 30	Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan	RE
Mar. 30	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI
Mar. 24	Guardant Health, Verana Health Collaborate to Advance Precision Medicine	MT
Mar. 24	Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data	CI
Mar. 16	Guardant Health and Manulife Launch Shield Multi-Cancer Detection Test in Hong Kong, Singapore and the Philippines	CI
Mar. 16	Guardant Health to Launch Multicancer Detection Test in Asia With Manulife Financial	MT
Mar. 16	Guardant Health launches Shield multi-cancer detection (Mcd) test in multiple markets in Asia with Manulife partnership	RE
Mar. 11	Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
Mar. 11	Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year	RE
Mar. 10	Guardant Health Inc Announces Shield Blood-Based Screening Test for Colorectal Cancer Is Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	CI
Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
Feb. 19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
Feb. 19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
Feb. 19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT